U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Office of the Chief Medical Officer
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Office of the Chief Medical Officer

Other FDA programs
FDA-TRACK Home

OCMO’s performance measures reported in the FDA-TRACK Program align to three categories: Combination Products, Orphan Product Development and Pediatric Therapeutics. Each activity is briefly described below with links to visualizations and dashboards. Explore the progress OCMO is making towards its performance goals on the FDA-TRACK website.

Office of Combination Products

Office of Combination Products (OCP) serves as a focal point for combination product (drug-device, biologic-device, drug-biologic, or drug-device-biologic products) issues for agency reviewers and industry.

Office of Orphan Products Development

Office of Orphan Products Development (OOPD) is dedicate to promoting the development of products (drugs, devices, biologics, and medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

Office of Pediatric Therapeutics

Office of Pediatric Therapeutics (OPT) primary mission is to assure access for children to innovative, safe and effective medical products.

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top